GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
Phase 3
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 836
- Registration Number
- NCT00476996
- Locations
- 🇺🇸
Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States
🇺🇸Center For Arthritis & Osteoporosis, Elizabethtown, Kentucky, United States
🇺🇸Arthritis Consultants, Saint Louis, Missouri, United States
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)
Phase 3
Completed
- Conditions
- Diabetes MellitusMacular Edema
- Interventions
- Drug: Sham injection
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 382
- Registration Number
- NCT00473382
A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT00473590
A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
Phase 3
Completed
- Conditions
- Macular EdemaDiabetes Mellitus
- Interventions
- Drug: Sham injection
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 377
- Registration Number
- NCT00473330
Study of Cobimetinib in Participants With Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT00467779
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
Phase 1
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Other: 2-deoxy-2-[18F]fluoro-D-glucose (FDG)Other: 3'-deoxy-3'-[18F]fluorothymidine (FLT)
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT00453362
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00452127
A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Anti-inflammatory drugs
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 578
- Registration Number
- NCT00443651
A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1026
- Registration Number
- NCT00443443
- Locations
- 🇺🇸
Rheumatology Associates, Dallas, Texas, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸MIMA Century Research Associates, Melbourne, Florida, United States
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT00434434
© Copyright 2025. All Rights Reserved by MedPath